While the authors suggested the use of TZD during the transition period to improve insulin homeostasis and to prevent excessive body condition score losses, their effect on VAT, inflammatory status, and metabolic disease prevention was not addressed by the study, thus requiring further elucidation. The gene discussed is INS; the disease is metabolic disease.